Gene therapy said widely reported Ergebnisse in Studie zur frontotemporalen Demenz Von Investing.com

PHILADELPHIA – Passage Bio, Inc. (NASDAQ:PASG), a gene therapies division, is presenting the donation at the annual conference of the European Society of Gene & Cell Therapy (ESGCT) as it conducts treatment and clinical data for its gene therapy product PBFT02. The therapy is designed to treat frontotemporal dementia with GRN mutations (FTD-GRN).

The clinical studies used in PBFT02 are the adeno-associated virus (AAV1) vector in representation of other vectors that use human progranulin in cerebrospinal virus (CSF). In models that reduce therapy of lysosomal histopathology and neuroinflammation, both are Schlüsselsel factors in FTD pathology. If the data from the PBFT02 come from the Verabreichung über de Cisterna magna (ICM) a Breite Verteilung in the nervous system, there is a weaker effect on the Hirn region, which is affected by FTD.

Vorläufige clinical data from the upliFT-D phase 1/2 study conducted, with PBFT02 in the entire range of tests and consistency, which removed the progranulin level in CSF fuhrte, was completed in 12 months after processing.

Will Chou, MD, CEO of Passage Bio, has discovered the potential of PBFT02 as the best therapeutic class with progranulin levels and acts on the einfluss of the ergebnisse in its clinical strategy. Due to the incurable soul that offers the potential of the therapy in more neurodegenerative treatments, the progranulin level is made more profitable.

The therapy that uses an AAV1 virus vector by the ICM dissemination of a functional GRN generation, which is treated by the disease, is that Progranulin levels are high and aggravate neurodegenerative neurodegenerative action. The präclinical data, the Entwicklung of PBFT02 is not available, but the presentation of the ESGCT-Kongress is shown in more detail.

Passage Bio comes from the Entwicklung of Einmal-Therapien, which arises from the fruitful Pathology neurodegenerative Erkrankungen. Der Ansatz und de Fortschritte des Unternehmensspiegeln sein Engagement broader, de unerfüllten Bedürfnisse von Patients mit diesen Erkrankungen zu addressedsieren.

The information in this article is based on a press conference by Passage Bio.

In others active nachrichten gab Passage Bio, Inc. Fortschritte in der Genetherapie voor Demenz bekannt, met verschenden präclinicalen und full clinical dating voor ihren fuhrenden Product Candidates PBFT02. If part of the costs is worth US$3.5 million and US$5.5 million, something will go wrong with outsourcing business activities and expanding the overall structure. In a strategic vision, Passage Bio-Treatment for GM1-Gangliosidosis, Krabbe-Krankheit and Metachromatic Leukodystrophy and GEMMA Biotherapeutics, Inc. That deal is concluded with an advance of 10 million dollars and a potentially comparable proceeds, which has been achieved by a gifted business partner.

Analysts at Canaccord Genuity have adopted their Kaufempfehlung for Passage Bio based on positive data from the upliFT-D Phase 1/2 Study. If you use one of the current options, one of the shares of the Nasdaq listing that is hereditary is a potential Delisting-Mitteilung company that has had a Aktienkurses under the inheritorlichen Mindest botspreis.

Passage Bio hat Thomas Kassberg als Class I-Director und Mitglied des Prüfungsausschussen ernannt. Kassberg, with a revolution in biotechnology, erhiels as Teil seines Vergütungspakets nicht-anreizbasierte Aktienoptionen. Schließlich hat Passage Bio the Zulassung von der US Food and Drug Administration has a gene therapy treatment PBFT02 for patients with frontotemporal demenz with C9orf72 gene mutations for evaluation. It dies like the young Entwicklungen in the laufenden Bemühungen von Passage Bio.

InvestingPro Insights

When the clinical and clinical data of the Passage Bio for PBFT02 are carried out, the financing effects of a complex picture can sometimes be damaged. Laut InvestingPro-Daten has deployed Passage Bio’s market capitalization at US$35.76 million, broadly mirroring its position as a Small-Cap-Biotech-Unternehmen.

InvestingPro-Tipps has given you the Passage Bio “schnell Bargeld verrennt” und “unter schwachen Grosswinnmarmen leidet”. These factories are intended for biotech companies in the city, which are investing heavily in research and development, not unintentionally. The change to the US dollar worth -$88.02 million in the quarter of 2024 was unpaid costs associated with the new generation of therapies.

Trotz die herausforderungen is erwähnenswert, dass Passage Bio “more Bargeld als Schulden in seiner Bilanz hält”, was a certain financial flexibility that beets could offer, while the pipeline would be more vorantreibt. The fact that the company was “placed on the market after a period of 52 weeks” was of interest to investors, who could be of interest after the potential investments in the biotech sector.

If you make any of the following analyses, you can give InvestingPro 10 other tips for the bio passage, which supports one of the financial positions and the market of the external economies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.